Local medical supply shortages make European research-based pharmaceutical (Rx) companies consider shifting their global production back home. At the same time a fundamental shift from blockbuster drugs to personalized medicine is taking place, enforcing a complete realignment of the business and operating model. Cell & Gene Therapy (CGT) is on the rise and the economic feasibility requires that highly innovative but costly research methods - such as mRNA-/T-CART technology - are applied with maximal efficiency. Patient-centric value chains work bi-directionally (e.g. complex cooling chains) and require both the processes of service providers (clinics) and the payers (health insurance companies) to be harmonized. Only under these conditions will a patient-centric ecosystem generate sustainable competitive advantages. You can trust our experts to help you establish new business and operating models. Together with you, we will design disruptive approaches and make your operating model future-ready.
- Digitalization, Industry 4.0, IIOT
- Streamline manufacturing and logistics
- Supply chains and manufacturing footprint
- Making product and service development fit for the future
- Cost reduction